Acquired scale isn't purchasing power: How healthcare platforms can capture procurement synergies

By Marco Bongiovanni

After a healthcare platform completes a series of acquisitions, the CFO may see one consolidated spend number. But the reality across the network can look very different: local contracts, different prices for identical products, physician-specific requirements, multiple buying channels, and unclear ownership of commercial decisions. The platform has acquired scale, but it has not necessarily acquired purchasing power.

Turning theoretical scale into real purchasing power requires more than supplier consolidation. Procurement value needs to be designed into the integration and operating model early, with a clear executive mandate, explicit enterprise and local decision rights, appropriate clinical involvement, and ownership of implementation and escalation. 

The objective is to create an organization capable of making consistent commercial decisions at scale while preserving appropriate clinical judgment. 

Across acquisition-built healthcare platforms, the initial opportunities are usually visible: different prices for the same products, fragmented suppliers, overlapping contracts, inconsistent rebates, duplicate applications, and locally negotiated services. 

Identifying those opportunities is rarely the hardest part. The challenge is whether the platform has the authority and capability to act on them. 

In one healthcare transformation, Procurement supported acquisitions, administered purchasing systems, and responded to tactical requests but lacked an explicit mandate to lead strategic category decisions. Contracts remained with business owners, Procurement was often involved too late to influence decisions, and clinically sensitive changes required approval and testing that had not been built into the sourcing process. 

The team was busy, but activity had not become authority. 

Before tackling difficult sourcing initiatives, leadership needs to agree on the ambition and pace, what Procurement can change, which decisions belong at the enterprise or practice level, where clinical approval is required, who owns implementation, and how unresolved decisions will be escalated. 

The appropriate level of executive involvement will vary. What matters is that delegation is explicit and leadership continues to support enterprise decisions when local resistance emerges, rather than reopening Procurement's mandate each time a difficult choice reaches a practice. 

Program-level alignment does not necessarily translate into category-level alignment. Leadership may support the overall transformation while individual initiatives stall because clinical requirements, financial baselines, decision rights, or implementation ownership remain unresolved. Executive alignment must therefore extend from the overall mandate to the decisions required to deliver each initiative. 

Healthcare leaders often ask whether purchasing should be centralized or remain local. That framing is too blunt. 

Within the same category, different parts of a decision may legitimately belong to different groups. Clinicians may define acceptable clinical requirements. Procurement may design the sourcing process and negotiate commercial terms. A business or category owner may recommend the operating model. An executive sponsor may resolve trade-offs between economics and disruption. Local teams may be responsible for ordering and adoption within an approved range. 

For each category, leaders should be able to answer five questions: 

1. Who defines the clinical and operational requirements? 
2. Who chooses the commercial strategy and conducts negotiations? 
3. Who makes the final supplier, product-panel, or service-model decision? 
4. Who can approve exceptions, and on what grounds? 
5. Who owns implementation across the network? 

If those questions cannot be answered, the category is not ready for an enterprise sourcing decision, regardless of how attractive the opportunity appears. 

In healthcare, we don't source in a vacuum. Commercial decisions sit within clinical workflows, physician preferences, and operating practices. Executive sponsorship creates authority, while clinical leadership creates legitimacy. Neither can replace the other in categories that affect care. 

Clinicians do not need to own every commercial decision. The challenge is to distinguish legitimate clinical requirements from commercial inconsistency. 

If several practices pay different prices for an identical implant, drug, or supply item, the platform can often harmonize those prices without asking physicians to change products. Product substitution is different. It may require evidence of equivalence, clinical review, trials, consideration of reimbursement or equipment dependencies, and an agreed exception process. 

The first enterprise standard, in other words, may be the decision-making process rather than the product. A platform can standardize how it evaluates suppliers, validates requirements, and approves exceptions before attempting to standardize every clinically influenced item. 

A supplier agreement does not create purchasing power if practices cannot, or do not, use it. 

Enterprise procurement must therefore extend beyond supplier selection and contract signature. The organization needs clear ownership, approved buying routes, and practical mechanisms for implementing decisions across the network. 

Who will load approved products and remove obsolete choices? Who will communicate with physicians and practice managers? Who will monitor compliance and approve exceptions? Who will intervene if a practice continues buying outside the agreement? 

If these questions remain unanswered, the decision is not implementation-ready. 

Local teams may have legitimate concerns about continuity, service, or clinical requirements. They may also be following the relationships and ordering methods that existed before acquisition. The operating model needs to distinguish between these situations and provide a clear route for resolving them. 

This turns sourcing from a succession of individual projects into an enterprise capability. 

The largest theoretical opportunity is not always the right place to start. 

Early initiatives can demonstrate that the platform is capable of acting as one organization. Harmonizing prices for identical items, consolidating a clearly duplicative service, or enforcing an approved buying channel can test ownership, decision rights, implementation, and adoption without immediately forcing difficult choices around clinical standardization. 

A smaller initiative that proves the operating model may create more strategic value than a larger sourcing event the organization is not yet equipped to execute. 

Over time, this capability also changes how the platform integrates acquisitions. Each new practice can enter a platform with established category ownership, decision rights, clinical governance, and approved buying routes, rather than introducing another set of undefined local purchasing practices. Procurement becomes part of the integration model rather than a succession of isolated sourcing projects. 

Acquisition creates the possibility of scale. Enterprise procurement turns that possibility into purchasing power: the ability to make sound commercial decisions repeatedly, implement them across a network, and preserve the clinical judgment that genuinely matters.